T1	Procedure 25 34	Treatment
E1	Procedure:T1 
T2	Negation 35 40	na√Øve
E2	Negation:T2 Negates:E1
T3	Or 41 43	or
E3	Or:T3 Arg:E2 Arg2:E4
T4	Drug 46 52	pegIFN
E4	Drug:T4 Name:T53 Temporality:E33
T5	Or 54 56	or
E5	Or:T5 Arg:E4 Arg2:E6
T6	Drug 57 60	IFN
E6	Drug:T6 Name:T33
T7	Or 63 69	and/or
E7	Or:T7 Arg:E4 Arg2:E8
T8	Drug 70 79	Ribavirin
E8	Drug:T8 Name:T34 Temporality:E33
T9	Drug 81 84	RBV
E9	Drug:T9 Name:T35
T10	Or 86 92	and/or
E10	Or:T10 Arg:E8 Arg2:E11
T11	Drug 93 103	sofosbuvir
E11	Drug:T11 Name:T36 Temporality:E33
T12	Drug 105 108	PRS
E12	Drug:T12 Name:T37
T13	Condition 137 140	CHC
E13	Condition:T13 Name:T38
T16	And 173 177	with
E16	And:T16 Arg:E13
T17	Or 178 180	or
E17	Or:T17 Arg:E16 Arg2:E35
T18	Modifier 189 200	compensated
E18	Modifier:T18 Modifies:T44
T19	Condition 201 210	cirrhosis
E19	Condition:T19 Name:T44
T20	Eq-Comparison 212 221	receiving
E20	Eq-Comparison:T20 Temporal-Period:T45
T21	Procedure 222 241	combination therapy
E21	Procedure:T21 Name:T46 Temporality:E20
T22	Drug 255 263	oral GLE
E22	Drug:T22 Name:T47
T23	Or 263 264	/
E23	Or:T23 Arg:E22 Arg2:E24
T24	Drug 264 267	PIB
E24	Drug:T24 Name:T48
T25	Eq-Comparison 395 408	up to 4 weeks
E25	Eq-Comparison:T25 Operator:T50 Value:T51 Temporal-Unit:T52
T26	Temporal-Connection 409 414	after
E26	Temporal-Connection:T26 Arg:E25 Arg2:E28
A1	Temporal-Connection-Type-Value E26 after
T27	Procedure 415 424	treatment
E27	Procedure:T27 Temporality:E28
T28	Eq-Comparison 425 435	initiation
E28	Eq-Comparison:T28 Temporal-Recency:T49
T29	Temporal-Connection 504 509	prior
E29	Temporal-Connection:T29 Arg:E30
A2	Temporal-Connection-Type-Value E29 before
T30	Study 532 537	study
E30	Study:T30 
T31	Negation 557 560	not
E31	Negation:T31 Negates:E42
T32	Procedure 637 648	therapeutic
E32	Procedure:T32 Name:T59
T33	Drug-Name 57 60	IFN
T34	Drug-Name 70 79	Ribavirin
T35	Drug-Name 81 84	RBV
T36	Drug-Name 93 103	sofosbuvir
T37	Drug-Name 105 108	PRS
T38	Condition-Name 137 140	CHC
T44	Condition-Name 201 210	cirrhosis
T45	Eq-Temporal-Period 212 221	receiving
A3	Eq-Temporal-Period-Value T45 present
T46	Procedure-Name 222 241	combination therapy
T47	Drug-Name 255 263	oral GLE
T48	Drug-Name 264 267	PIB
T50	Eq-Operator 395 400	up to
A5	Eq-Operator-Value T50 LTEQ
T51	Eq-Value 401 402	4
T52	Eq-Temporal-Unit 403 408	weeks
A6	Eq-Temporal-Unit-Value T52 week
T53	Drug-Name 46 52	pegIFN
R1	Abbrev-Of Arg1:E9 Arg2:E8	
R2	Abbrev-Of Arg1:E12 Arg2:E11	
T54	Eq-Comparison 110 121	experienced
E33	Eq-Comparison:T54 Temporal-Period:T55
T55	Eq-Temporal-Period 110 121	experienced
A7	Eq-Temporal-Period-Value T55 past
T56	And 122 126	with
E34	And:T56 Arg:E12 Arg2:E13
T57	Negation 181 188	without
E35	Negation:T57 Negates:E19
T14	Modifier 142 151	genotypes
E14	Modifier:T14 Modifies:T38
T15	Modifier 152 153	1
E15	Modifier:T15 Modifies:T38
T39	Modifier 155 156	2
E36	Modifier:T39 Modifies:T38
T40	Modifier 158 159	3
E37	Modifier:T40 Modifies:T38
T41	Modifier 161 162	4
E38	Modifier:T41 Modifies:T38
T42	Modifier 164 165	5
E39	Modifier:T42 Modifies:T38
T43	Modifier 170 171	6
E40	Modifier:T43 Modifies:T38
T58	Or 167 169	or
E41	Or:T58 Arg:E39 Arg2:E40
R3	Using Arg1:E21 Arg2:E22	
R4	Using Arg1:E21 Arg2:E24	
T49	Eq-Temporal-Recency 425 435	initiation
A4	Eq-Temporal-Recency-Value T49 first-time
T59	Procedure-Name 637 648	therapeutic
T60	Study 649 654	trial
E42	Study:T60 Study-Of:E32
